Horizon Therapeutics Public Limited Company (HZNP)

108.02
NASDAQ
Prev Close 109.71
Day Low/High 106.61 / 109.45
52 Wk Low/High 66.41 / 111.70
Exchange NASDAQ
Shares Outstanding 225.89B
Market Cap 24.78B
P/E Ratio 19.63
Div & Yield N.A. (N.A)
With Martin Shkreli Long Gone, Retrophin is an 'Interesting Opportunity'

With Martin Shkreli Long Gone, Retrophin is an 'Interesting Opportunity'

Retrophin (RTRX), the biotech company that used to be run by indicted hedge fund manager Martin Shkreki, provides an interesting investment opportunity.

Jim Cramer Says Don't Rush in to Buy Stocks in Monday Selloff

Jim Cramer Says Don't Rush in to Buy Stocks in Monday Selloff

Jim Cramer says don’t rush into the stock market in Monday's trading session looking for bargains in the midst of a selloff.

Bah Humbug Macy's, Jim Cramer Says the Holiday Season Belongs to Amazon

Bah Humbug Macy's, Jim Cramer Says the Holiday Season Belongs to Amazon

Jim Cramer, portfolio manager at TheStreet’s Action Alerts PLUS and host of CNBC’s ‘Mad Money’ said Amazon (AMZN) stock is going higher because the company’s business model is so good.

Why Biotech Has Bottomed

Why Biotech Has Bottomed

Investors should ignore the temporary issues that have knocked the sector down.

Why Biotech Has Bottomed

Why Biotech Has Bottomed

Investors should ignore the temporary issues that have knocked the sector down.

Targets of Market Hatred Can Change Daily

Targets of Market Hatred Can Change Daily

It used to be industrials, now it's health care.

Jim Cramer Says Tech Giants Microsoft, IBM Should Make Acquisitions

Jim Cramer Says Tech Giants Microsoft, IBM Should Make Acquisitions

Jim Cramer says Microsoft (MSFT) will report a decent quarter, thanks to Windows 10, but he wishes the company would make an acquisition.

A Small Pharma Stock With Big Potential

A Small Pharma Stock With Big Potential

Pernix looks poised for a strong 2016.

How to Build a Good Foundation in Biotechs

How to Build a Good Foundation in Biotechs

A so-called "pyramid strategy" can help you enter the depressed sector.

Hedge Funds Doing Battle Over Ailing Stocks

Hedge Funds Doing Battle Over Ailing Stocks

There's blood in the water.

The Biotechs Are Being Taken Out and Shot

All you can do is wait until they bottom out.

Horizon and ANI Appeal in Pharma Selloff

Horizon and ANI Appeal in Pharma Selloff

Some smaller biotechs offer good value at current levels.

Market Wrap: Stocks Sink Across the Board

Market Wrap: Stocks Sink Across the Board

Materials and technology names led the way down on the session.

Market Wrap: Stocks Make Quick Recovery

Market Wrap: Stocks Make Quick Recovery

Second-half rebound erases losses.

Anything Goes in This Merger Era

If anything, I am being too small-minded when it comes to mergers.

Where the Money Was Made the Last 5 Years

Where the Money Was Made the Last 5 Years

Only one fund category (of 20) has beaten the S&P 500 over half a decade.

Horizon Pharma Is Ready for a Boost

Horizon Pharma Is Ready for a Boost

Horizon Pharma's volume trends have been very positive.

Say It With Me: Specialty Pharma

These companies are the hottest thing going.

Mylan Deal the Rx for Drug Stocks

Mylan Deal the Rx for Drug Stocks

Even the second-tier biotechs are taking off.

Feeling Good About Pharmaceuticals

With so much M&A action, now's the time to invest in the sector.

Market Wrap: Out Like a Lion

Stocks post solid gains with the S&P breaking a losing streak.

Hard to Find Any Negatives

Hard to Find Any Negatives

Price action tells the real story of the market.

A Classic Melt-Up

A Classic Melt-Up

Hopeful bears were dead wrong again.

A Very Shallow Pullback

A Very Shallow Pullback

Conditions still favor the bulls.

The Slow-Motion Rally Rolls On

The Slow-Motion Rally Rolls On

Even if you are a raging bull, it is still tricky to navigate this market.

At a Loss

At a Loss

The major indices are out of step with the underlying action.

A Look at What the Big Boys Have Been Buying

Here are five large purchases that were made by hedge funds recently.

Navigating a Sea of Red

Navigating a Sea of Red

The market is starting to stabilize, but the action remains skittish.

Seems Like a Run-of-the-Mill Pullback

Seems Like a Run-of-the-Mill Pullback

There is no reason to believe the market is topping out. It just needs to digest its gains.

The Next Big Thing in Biotech: Amarin, Onyx

The Next Big Thing in Biotech: Amarin, Onyx

Adam Feuerstein, senior columnist for TheStreet, says Amarin and Onyx are the next big things in biotech.